Pharmaceuticals, Biotechnology & Life Sciences

CytoDyn’s April 2026 prospectus supplement reveals modest cash growth, new stock issuances, and regulatory stability—offering investors insight into its HIV‑therapy R&D strategy and market positioning.

Trulieve Cannabis Corp capitalizes on Colorado’s new hospital‑access law for terminal patients, expanding market reach and boosting investor confidence in medical cannabis.

Teva Pharmaceutical: Institutional shifts, BofA’s raised price target, and a P/E of 25.14 make it a discounted strong‑buy for value‑seeking investors.

Discover Anavex Life Sciences’ latest breakthroughs in Alzheimer’s, Parkinson’s, and rare CNS disorders—join their 2026 virtual healthcare conference for exclusive insights.

Beleave Inc. sees a sharp rise in its OTC stock after new strategic moves in medical cannabis and clinic operations—could this small cap signal future growth?

Calidi Biotherapeutics unveils its RedTail virotherapy platform, a targeted gene‑therapy breakthrough for solid tumors, advancing IL‑15 and T‑cell engagers toward clinical trials.

OSR Holdings Inc. (OSR) is a blank‑check company targeting growth in healthcare. With a volatile stock yet a clear acquisition strategy, it offers investors a chance to profit from future buyouts in the rapidly evolving healthcare sector.

Explore Amylyx Pharmaceuticals’ strategic move to the 25th Annual Needham Virtual Healthcare Conference, highlighting its ALS research, investor outreach, and future prospects.

Ardelyx’s new partnership and promising preclinical data signal a boost for its mineral‑metabolism drugs, while disciplined capital strategy keeps investors focused on long‑term growth.

Johnson & Johnson stock steadies at $241.3, eyes a $251.71 52‑week high, amid mixed institutional trades and fresh earnings forecasts.